Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. - Wikidata - wikimedia - TriplyDB

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.

http://www.wikidata.org/entity/Q34627677

about

Immunotherapy for Gastroesophageal Cancer Therapeutic vaccines for gastrointestinal cancers.Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.Trial watch: Peptide vaccines in cancer therapy Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.NY-ESO-1 antibody as a novel tumour marker of gastric cancer.In vivo enhancement of the MAGE-specific cellular immune response by a recombinant MAGE1-MAGE3-TBHSP70 tumor vaccine.Sperm protein 17, MAGE-C1 and NY-ESO-1 in hepatocellular carcinoma: expression frequency and their correlation with clinical parameters.Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.Novel adjuvants & delivery vehicles for vaccines development: a road ahead Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma.Inducible expression of cancer-testis antigens in human prostate cancer.Overexpression of Testes-Specific Protease 50 (TSP50) Predicts Poor Prognosis in Patients with Gastric Cancer.Prostate cancer vaccines in clinical trials.5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies.EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.Clinical relevance of antigen spreading pattern induced by CHP-MAGE-A4 cancer vaccination.NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.Translational nanoparticle engineering for cancer vaccines.Research progress of self-assembled nanogel and hybrid hydrogel systems based on pullulan derivatives.Current status of immunotherapy and immune biomarkers in gastro-esophageal cancers.

P2860

Q28069873-CBC73374-A3E4-424D-B859-FEEB418BD54C Q35691248-05CA09DE-F9B9-485C-BC5E-3FF8D0065BEE Q35733359-31706F4E-9F0F-4B49-A97B-26FF41F4B3E7 Q36476100-74F54253-60EC-4037-BDCA-EC0BDD9ED17F Q36596837-158DE2F4-ABE9-47ED-95A2-E59877B2B5EA Q36746749-40F81635-1EA8-4493-9D8B-9CD831B44B88 Q37018060-1FDF78E9-2D3E-410A-99B2-AF761E0631EB Q37054571-19532A79-FD54-4AB0-AEE2-B2C5689EE834 Q37585487-92570B8D-183C-4A8B-86F7-CEB63DCC4300 Q37591955-58FA9B74-F284-48D6-96FB-2860DB8AC04A Q37592383-62B7A87B-6A1F-4A2E-B01A-DD4132927E60 Q37625469-07D26796-4E37-4D18-8C95-F8AC659560C2 Q37686238-E06CAD8E-DF4E-4150-98A2-AAB2CA5A1674 Q37700791-D8F55FC2-5F44-4B14-86D3-34845589055F Q38036690-37C51C16-8851-4479-B61E-5019C83D3116 Q38588894-4CB2115C-BA22-49C3-89FA-BB9A12AB18CF Q39160149-8E5B30B0-E349-4CF6-9501-59FFBDA94A0F Q40903761-DFB7C210-BDB1-44C7-A775-FB0E1DCDAD44 Q44264589-FD103A2E-C2F0-4D1A-9326-FFF09C27EE32 Q46720677-C9E6A2DE-69D8-4E26-AD3A-95B5D8131AE4 Q50044627-A7DBAAE7-C8AE-49A6-A396-2AC44C1FE653 Q52643527-5A5931DC-0AAF-49CE-8CD6-458916C27CCC

P2860

Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.

http://www.wikidata.org/entity/Q34627677

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@ast

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@en

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@nl

type

label

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@ast

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@en

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@nl

prefLabel

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@ast

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@en

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@nl

P1433

Q34627677-1FA05AF0-FE2F-4BED-9733-CA2E267A912B

P1476

Q34627677-1B8B2076-44FF-43C8-B94D-EB235DFDF000

P2093

Q34627677-1798A986-7900-4EF2-A9BD-E548218BC2C8

Q34627677-3066808C-784E-443D-BB62-397FD516CD99

Q34627677-3715AD4D-DFB8-44B1-A0DC-54E0A4ABD2D7

Q34627677-38AC371E-391D-4D18-BC4C-2CD8DFA14C46

Q34627677-47435975-242A-4A60-821B-8B7723C620EF

Q34627677-518B387F-F597-4AB9-8E57-B0A889998B36

Q34627677-6DD64382-2253-4960-8E76-9003FE74DB99

Q34627677-7053EE56-B2E4-4DB1-97F2-E6101D87EA83

Q34627677-7BEE20E9-83DC-4D5A-9E90-D9748D87FE93

Q34627677-843C3358-B121-41FE-BA2E-D5ED900519FC

P2860

Q34627677-17FF2704-9E85-4358-8151-AAE38ADD47FA

Q34627677-19DB8332-0703-4F5C-A069-6CE139083F80

Q34627677-1A56C904-4F2A-43F9-91A2-925417FB2FB5

Q34627677-2080EB4C-0E6D-4D6C-9C81-CBD7322411E3

Q34627677-353CEB54-37AB-4CA0-A118-7AD075AD07D1

Q34627677-3970180F-88EE-4FE3-B806-42AD1E12316A

Q34627677-43C97FEA-32D4-4B43-A150-D9F134966010

Q34627677-4B81FE0F-3073-4C83-A3B6-D8CADE3DDD45

Q34627677-66B7A349-D356-4CFE-A9DE-EC8942206263

Q34627677-66D4D56C-6528-4F96-976F-DF1E7824A8F3

P304

Q34627677-7D1CDF73-75C7-40D1-9B36-D4AFDDCB18A7

P31

Q34627677-3623D4E2-A557-4FAE-831D-BB03453E9DEC

P356

Q34627677-CE1CB22E-905B-425E-B4FD-8595EC87E84B

P433

Q34627677-E5071292-95BD-4340-9C23-514464F302FA

P478

Q34627677-C78A70D1-69F6-492A-8A9A-DC1EADBD397A

P577

Q34627677-3A83D08D-2933-4E8A-A1D1-ECB5815DF80C

P5875

Q34627677-D847EB0D-75DE-4B4A-BCC8-41FB8560C595

P698

Q34627677-82F5FDB2-49F5-4C14-91C0-F4CD192BDB1D

P356

P1433

International Journal of Cancer

P1476

Heteroclitic serological respo ...... NY-ESO-1 protein vaccination.

@en

P2093

Achim A Jungbluth

http://www.w3.org/2001/XMLSchema#string

Akiko Uenaka

http://www.w3.org/2001/XMLSchema#string

Eiichi Nakayama

http://www.w3.org/2001/XMLSchema#string

Erika Ritter

http://www.w3.org/2001/XMLSchema#string

Gerd Ritter

http://www.w3.org/2001/XMLSchema#string

Hiroshi Miyata

http://www.w3.org/2001/XMLSchema#string

Hiroyoshi Nishikawa

http://www.w3.org/2001/XMLSchema#string

Hisashi Wada

http://www.w3.org/2001/XMLSchema#string

Junji Kawada

http://www.w3.org/2001/XMLSchema#string

Linda Pan

http://www.w3.org/2001/XMLSchema#string

P2860

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity.

Seromic profiling of ovarian and pancreatic cancer.

CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients.

NY-ESO-1: review of an immunogenic tumor antigen.

Epitope spreading in immune-mediated diseases: implications for immunotherapy.

In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines.

Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients.

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

P304

584-592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.26074

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

130

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50410514

http://www.w3.org/2001/XMLSchema#string

P698

21413013

http://www.w3.org/2001/XMLSchema#string